Clinical Trials · NCT00004635
Thalidomide for the Treatment of Hormone-Dependent Prostate Cancer
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- National Cancer Institute (NCI)
- Enrollment
- 159
- Start date
- Mar 2000
- Locations
- 9 sites, United States
- Primary endpoint
- Time to Progression